These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26700564)

  • 1. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
    Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
    Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
    Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
    Bagher AM; Laprairie RB; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Jun; 89(6):652-66. PubMed ID: 27053685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.
    Laprairie RB; Kelly ME; Denovan-Wright EM
    Neuropharmacology; 2013 Sep; 72():47-57. PubMed ID: 23602984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons.
    Straiker A; Dvorakova M; Zimmowitch A; Mackie K
    Mol Pharmacol; 2018 Jul; 94(1):743-748. PubMed ID: 29669714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
    Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
    PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing CB1 receptor GIRK channel responses to receptor internalization using a kinetic imaging assay.
    Andersen HK; Vardakas DG; Lamothe JA; Perault TEA; Walsh KB; Laprairie RB
    Sci Rep; 2024 Aug; 14(1):18314. PubMed ID: 39112591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
    Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments.
    Bagher AM; Young AP; Laprairie RB; Toguri JT; Kelly MEM; Denovan-Wright EM
    J Neurosci Res; 2020 Dec; 98(12):2496-2509. PubMed ID: 32881145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
    Carroll CB; Zeissler ML; Hanemann CO; Zajicek JP
    Neuropathol Appl Neurobiol; 2012 Oct; 38(6):535-47. PubMed ID: 22236282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
    Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
    Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of beta-arrestin1 deletion on acute cannabinoid activity, brain cannabinoid receptors and tolerance to cannabinoids in mice.
    Breivogel CS; Vaghela MS
    J Recept Signal Transduct Res; 2015 Feb; 35(1):98-106. PubMed ID: 25779032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibitory action of exo- and endocannabinoids on [³H]GABA release are mediated by both CB₁and CB₂receptors in the mouse hippocampus.
    Andó RD; Bíró J; Csölle C; Ledent C; Sperlágh B
    Neurochem Int; 2012 Jan; 60(2):145-52. PubMed ID: 22133429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
    Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
    Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.